ArticleFrontiers in pharmacology2023
Identification of the main flavonoids of
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Total flavonoids ofPharmaceutical biology · 2026Article
- Mapping the kidney distribution of Huangkui capsule-derived components in diabetic nephropathy treatment: a mass spectrometry imaging and metabolomics approach nominates quercetin and its conjugates as bioactive candidates.Analytical and bioanalytical chemistry · 2026Article
- Enzyme-Assisted Ultrasonic Extraction of a Polysaccharide-Rich Extract fromMolecules (Basel, Switzerland) · 2026Article
- Article
- Huangkui capsule mitigates diabetic nephropathy via epigenetic therapy effects.Frontiers in pharmacology · 2026Article
- Integrative analysis of morphological traits and targeted flavonoid profiles reveals chemotaxonomic signatures inFrontiers in plant science · 2026Article
- Article
- Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Molecular mechanisms and multi-target therapeutic strategies of diabetic nephropathy: from pathogenesis to precision interventions.Frontiers in pharmacology · 2025Review
- Total flavonoids fromFrontiers in medicine · 2025Article
- TangNaikang Formula Alleviates Podocyte Injury in Diabetic Nephropathy by Modulating the SHIP2/PI3K/AKT Pathway.Journal of diabetes research · 2025Article
- Multi-omics reveals total flavones from Abelmoschus manihot (L.) Medik. [Malvaceae] ameliorate MAFLD via PI3K/AKT/mTOR-mediated autophagy.Frontiers in pharmacology · 2025Article
- Therapeutic potential ofFrontiers in pharmacology · 2025Review
- Research progress in the treatment of lipid metabolism disorder in patients with diabetic kidney disease by the integrated traditional Chinese and Western medicine.Frontiers in endocrinology · 2025Review
- Effects ofFrontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.